LENZ Therapeutics, Inc. (LENZ)
USD 23.24
(14.71%)
USD 23.24
(14.71%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -90 Million | -87.98 Million | -52.85 Million | -8.72 Million | -19 Thousand |
| Net Income | -124.65 Million | -101.05 Million | -70.76 Million | -68.37 Million | -109 Thousand |
| Depreciation & Amortization | 2.4 Million | 8.34 Million | 734 Thousand | 121 Thousand | - |
| Deferred income taxes | - | -17.21 Million | 161 Thousand | - | - |
| Stock-based compensation | - | 721 Thousand | 196 Thousand | - | - |
| Change in working capital | -39.22 Million | -7.2 Million | -2.49 Million | 1.7 Million | 10 Thousand |
| Other non-cash items | 78.63 Million | 28.43 Million | 19.31 Million | 57.47 Million | 92 Thousand |
| Investing Cash Flow | 226.34 Million | -241.86 Million | -5.74 Million | -1.54 Million | - |
| Investments in PPE | -10.85 Million | -6.59 Million | -5.74 Million | -1.54 Million | - |
| Acquisitions | 1.9 Million | - | - | - | - |
| Investment purchases | -28.12 Million | -405.51 Million | - | - | - |
| Sales/Maturities of investments | 263.42 Million | 170.25 Million | - | - | - |
| Other Investing Activities | - | - | - | - | - |
| Financing Cash Flow | 190 Thousand | 597 Thousand | 417.46 Million | 30.07 Million | - |
| Debt repayment | - | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -67 Thousand | -79 Thousand | - | - | - |
| Common Stock Issuance | 257 Thousand | 676 Thousand | 417.16 Million | 30.07 Million | - |
| Other Financing Activities | - | - | 306 Thousand | - | - |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | -2.35 Million | 194 Thousand | 1.82 Million | 594 Thousand | -12 Thousand |
| Inventory | - | - | - | - | - |
| Other working capital | -36.86 Million | -7.4 Million | -4.32 Million | 1.11 Million | 22 Thousand |
| Cash at beginning of period | 47.73 Million | 376.97 Million | 19.81 Million | 6000.00 | 25 Thousand |
| Cash at end of period | 185.86 Million | 47.73 Million | 376.97 Million | 19.81 Million | 6000.00 |
| Capital Expenditure | -10.85 Million | -6.59 Million | -5.74 Million | -1.54 Million | - |
| Effect of forex changes on cash | 1.6 Million | - | -1.71 Million | - | - |
| Net cash flow / Change in cash | 138.13 Million | -329.24 Million | 357.15 Million | 19.81 Million | -19 Thousand |
| Free Cash Flow | -100.86 Million | -94.57 Million | -58.59 Million | -10.26 Million | -19 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -10.25 Million | -16.64 Million | -22.91 Million | -124.65 Million | -22.48 Million | -55.31 Million |
| Depreciation & Amortization | 18 Thousand | 5000.00 | 142 Thousand | 2.4 Million | 800 Thousand | 2.09 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.59 Million | 947 Thousand | - | - | 494 Thousand | 189 Thousand |
| Change in working capital | -6.19 Million | -9.01 Million | -42.5 Million | -39.22 Million | 2.85 Million | 1.48 Million |
| Other non-cash items | -959 Thousand | - | 23.19 Million | 78.63 Million | 8.79 Million | 42.76 Million |
| Investing Cash Flow | -98.39 Million | 18 Million | 47.08 Million | 226.34 Million | 63.87 Million | 72.22 Million |
| Investments in PPE | -133 Thousand | - | -50 Thousand | -10.85 Million | -4.81 Million | -5.61 Million |
| Acquisitions | - | - | 679 Thousand | 1.9 Million | 888 Thousand | 337 Thousand |
| Investment purchases | - | - | 1000.00 | -28.12 Million | -19.41 Million | -1000.00 |
| Sales/Maturities of investments | 13 Million | 18 Million | 46.45 Million | 263.42 Million | 67.8 Million | 77.5 Million |
| Other Investing Activities | -111.25 Million | - | - | - | - | - |
| Financing Cash Flow | -2.13 Million | 171.26 Million | 66 Thousand | 190 Thousand | 8000.00 | 124 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -67 Thousand | -8000.00 | -51 Thousand |
| Common Stock Issuance | -3.56 Million | 53.38 Million | 66 Thousand | 257 Thousand | 16 Thousand | 175 Thousand |
| Other Financing Activities | -1.98 Million | 117.45 Million | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -2.68 Million | -1.26 Million | -3.5 Million | -2.35 Million | 2.23 Million | -498 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -3.51 Million | - | -39 Million | -36.86 Million | 623 Thousand | 1.98 Million |
| Cash at beginning of period | 200.47 Million | 35.14 Million | 182.98 Million | 47.73 Million | 128.5 Million | 69.81 Million |
| Cash at end of period | 84.14 Million | 200.47 Million | 185.86 Million | 185.86 Million | 182.98 Million | 128.5 Million |
| Capital Expenditure | -133 Thousand | - | -50 Thousand | -10.85 Million | -4.81 Million | -5.61 Million |
| Effect of forex changes on cash | - | - | 1.6 Million | 1.6 Million | - | - |
| Net cash flow / Change in cash | -116.32 Million | 165.33 Million | 2.87 Million | 138.13 Million | 54.48 Million | 58.69 Million |
| Free Cash Flow | -15.92 Million | -23.93 Million | -45.92 Million | -100.86 Million | -14.21 Million | -19.26 Million |
JTS
BYOGF
7284
1780
ROUTE
CRSR